Literature DB >> 23488972

Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs.

Lisa F Shubitz1, Michael E Roy, David E Nix, John N Galgiani.   

Abstract

Nikkomycin Z (NikZ) is a chitin synthase inhibitor with antifungal efficacy against Coccidioides spp. and other endemic fungi. Dogs suffer a rate and range of natural coccidioidomycosis similar to humans and were considered an excellent model for initially testing NikZ against naturally acquired disease. Twelve dogs with coccidioidal pneumonia that had been present for an average of three months were treated with 250 mg (5-15 kg) or 500 mg (> 15-30 kg) twice daily for 60 days. Nine dogs completed the course of treatment and seven dogs had improvement in disease based on radiographs, clinicopathological parameters, physical examination findings, and subjective assessment by owners; three dogs had resolution or near resolution of disease. Based on this small study, NikZ shows efficacy to treat naturally acquired coccidioidomycosis and merits further development for trials in humans.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23488972     DOI: 10.3109/13693786.2013.770610

Source DB:  PubMed          Journal:  Med Mycol        ISSN: 1369-3786            Impact factor:   4.076


  13 in total

1.  Modulation of Alternaria infectoria cell wall chitin and glucan synthesis by cell wall synthase inhibitors.

Authors:  Chantal Fernandes; Jorge Anjos; Louise A Walker; Branca M A Silva; Luísa Cortes; Marta Mota; Carol A Munro; Neil A R Gow; Teresa Gonçalves
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

Review 2.  Drugs in Clinical Development for Fungal Infections.

Authors:  Maria F Gonzalez-Lara; Jose Sifuentes-Osornio; Luis Ostrosky-Zeichner
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

3.  Structural basis for inhibition and regulation of a chitin synthase from Candida albicans.

Authors:  Zhenning Ren; Abhishek Chhetri; Ziqiang Guan; Yang Suo; Kenichi Yokoyama; Seok-Yong Lee
Journal:  Nat Struct Mol Biol       Date:  2022-07-04       Impact factor: 18.361

4.  Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials.

Authors:  Lisa F Shubitz; Hien T Trinh; Robert H Perrill; C Michael Thompson; Nathan J Hanan; John N Galgiani; David E Nix
Journal:  J Infect Dis       Date:  2014-01-12       Impact factor: 5.226

5.  Efficacy of the Investigational Antifungal VT-1161 in Treating Naturally Occurring Coccidioidomycosis in Dogs.

Authors:  Lisa F Shubitz; Michael E Roy; Hien T Trinh; William J Hoekstra; Robert J Schotzinger; Edward P Garvey
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

Review 6.  Identification and characterization of enzymes involved in the biosynthesis of pyrimidine nucleoside antibiotics.

Authors:  M McErlean; X Liu; Z Cui; B Gust; S G Van Lanen
Journal:  Nat Prod Rep       Date:  2021-07-21       Impact factor: 15.111

Review 7.  Investigational Agents for the Treatment of Resistant Yeasts and Molds.

Authors:  Garret T Seiler; Luis Ostrosky-Zeichner
Journal:  Curr Fungal Infect Rep       Date:  2021-05-28

8.  Conserved Mechanism of 2'-Phosphorylation-Aided Amide Ligation in Peptidyl Nucleoside Biosynthesis.

Authors:  Matthew M Draelos; Anyarat Thanapipatsiri; Kenichi Yokoyama
Journal:  Biochemistry       Date:  2021-07-09       Impact factor: 3.321

Review 9.  Hope on the Horizon: Novel Fungal Treatments in Development.

Authors:  Adriana M Rauseo; Ariella Coler-Reilly; Lindsey Larson; Andrej Spec
Journal:  Open Forum Infect Dis       Date:  2020-01-12       Impact factor: 3.835

Review 10.  Nikkomycin Z-Ready to Meet the Promise?

Authors:  David J Larwood
Journal:  J Fungi (Basel)       Date:  2020-10-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.